title: Are epsins a therapeutic target for tumor angiogenesis?
abstract: Solid tumor growth requires the formation of new blood vessels to supply nutrients and oxygen to the malignant cells; one approach to cancer therapy is to block this process by inhibiting VEGF signaling. In this issue of the JCI, Pasula et al. demonstrate a surprising role of epsins--proteins involved in endocytosis--in tumor angiogenesis via their modulation of VEGF signaling. Their findings suggest that these proteins might represent a new target for the development of cancer therapeutics.
authors.affiliation: Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. nancy_demore@med.unc.edu
authors.forename: Nancy
authors.initials: N
authors.lastname: Klauber-Demore
mesh_terms: D033942:Adaptor Proteins, Vesicular Transport / Q000235:genetics*; D000818:Animals; D049109:Cell Proliferation; D061307:Human Umbilical Vein Endothelial Cells / Q000378:metabolism*; D006801:Humans; D008297:Male; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology*
chemical_list: D033942:Adaptor Proteins, Vesicular Transport; C577774:Epn2 protein, mouse; D042461:Vascular Endothelial Growth Factor A; C114154:epsin; C467480:vascular endothelial growth factor A, mouse